This page features ACC's full coverage of the latest science from Transcatheter Cardiovascular Therapeutics (TCT) 2026, taking place Oct. 31 to Nov. 3, 2026 in San Diego, CA.

A new international expert consensus document refines and updates how heart failure is identified and classified, aiming to improve prevention, diagnosis and management of heart failure worldwide.

People with cardiometabolic disorders—such as obesity, diabetes and heart disease—could increase their chances of living longer by adopting a healthy plant-based diet, according to a study being ...

In this week’s View, Dr. Eagle looks at a recent JACC: Advances Viewpoint that examines the challenges associated with implementing revisions to the definition of first medical contact (FMC) ...

Earn continuing education credits Prepare for initial and continuous certification Stay current with the latest clinical science and guidelines Connect with peers through meetings, events and ...

Interventional science was the focus of a Hot Line Session at ESC Congress 2026, with studies shedding light on milvexian with antiplatelet therapy following an acute coronary event; aspirin omission ...

Spironolactone, an aldosterone blocker, compared with placebo, did not show any significant improvement in terms of heart failure (HF) hospitalizations and cardiovascular death at 24 months in ...

The U.S. Food and Drug Administration (FDA) has approved baxdrostat, a first-in-class oral aldosterone synthase inhibitor, as an add-on therapy for hypertension in adults whose blood pressure (BP) is ...

A robust body of observational and Mendelian randomization data establishes a causal relationship between elevated Lp(a) and ASCVD, ischemic stroke and calcific aortic valve stenosis (CAVS). 3 A ...

Pulmonary-artery denervation, in addition to guideline-directed medical therapy, resulted in fewer events of clinical worsening than medical therapy alone in patients with pulmonary hypertension ...

Older patients with coronary artery disease (CAD) for whom PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred, according to findings from the PRO-TAVI study ...

About 50% of U.S. adults will develop high BP during their lifetime. High BP is the most prevalent and modifiable risk factor for cardiovascular disease and all-cause mortality. The overarching BP ...